Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia.
BACKGROUND
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells. Approximately half of all adult AML patients have a normal karyotype (NK-AML) and an intermediate risk prognosis.


OBJECTIVE
To determine the incidence and prognostic significance of NPM1 and FLT3-ITD mutations in a population of patients with NK-AML.


METHODS
FLT3-ITD and NPM1 mutation status was retrospectively sought in presentation samples from 44 NK-AML patients.


RESULTS
FLT3-ITD and NPM1 mutations were detected in 45.5 and 54.5% of patients, respectively, allowing stratification according to genotype.


CONCLUSIONS
FLT3-ITD and NPM1 mutation status can be defined in NK-AML. Prospective screening for these mutations is advocated in all NK-AML patients, as the genotype is of clinical importance when considering treatment options including stem cell transplantation.
Haslam
K
K
Cancer Molecular Diagnostics, Central Pathology Laboratory, St. James Hospital, Dublin, Ireland. khaslam@stjames.ie
Chadwick
N
N
Kelly
J
J
Browne
P
P
Vandenberghe
E
E
Flynn
C
C
Conneally
E
E
Langabeer
S E
SE
D000293:Adolescent; D000328:Adult; D000368:Aged; D004587:Electrophoresis, Agar Gel; D005260:Female; D005838:Genotype; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D010750:Phosphoproteins / Q000235:genetics*; D011379:Prognosis; D012189:Retrospective Studies; D016036:Seroepidemiologic Studies; D014997:XYY Karyotype; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D010750:Phosphoproteins; D000090243:Nucleophosmin; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3
Blood. 2007 Feb 1;109(3):874-85
17008539
Nat Rev Cancer. 2003 Sep;3(9):650-65
12951584
Blood. 2005 Dec 1;106(12):3733-9
16076867
Blood. 1999 May 1;93(9):3074-80
10216104
Blood. 2005 Dec 1;106(12):3740-6
16051734
Lancet. 2006 Nov 25;368(9550):1894-907
17126723
Br J Haematol. 2007 Jun;137(5):387-400
17488484
J Mol Diagn. 2008 May;10(3):236-41
18403605
Blood. 2002 Dec 15;100(13):4372-80
12393388
N Engl J Med. 2008 May 1;358(18):1909-18
18450602
Blood. 2010 Jul 22;116(3):354-65
20385793
Blood. 2006 May 15;107(10):4011-20
16455956
Blood. 2007 Jan 15;109(2):431-48
16960150
N Engl J Med. 2005 Jan 20;352(3):254-66
15659725
Clin Chem Lab Med. 2009;47(11):1333-41
19817644
Blood. 2009 May 21;113(21):5250-3
19279329
Blood. 2002 Jul 1;100(1):59-66
12070009
Blood. 2010 Jan 21;115(3):453-74
19880497
Blood. 2001 Sep 15;98(6):1752-9
11535508
Blood. 2008 Mar 1;111(5):2776-84
17957027
Blood. 1998 Oct 1;92(7):2322-33
9746770